With lean staff, low cash, Axcella races ahead with Long Covid drug

Axcella Therapeutics Inc. has one of the most advanced potential drugs for Long Covid in the industry. It also has only enough cash runway to get it through the second quarter of this year, making for a mad-dash effort to get that drug through clinical trials.
Click here to view original post